Search

Your search keyword '"Cervantes F."' showing total 1,080 results

Search Constraints

Start Over You searched for: Author "Cervantes F." Remove constraint Author: "Cervantes F."
1,080 results on '"Cervantes F."'

Search Results

51. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

52. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

70. Characterization of Photoreceivers for LISA

78. Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain: Abstracts of Symposia and free communications

81. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

83. Concentración preoperatoria de fibrinógeno plasmático como predictor de sangrado en artroplastía total de cadera.

87. Essential thrombocythaemia with mutation in MPL : clinicopathological correlation and comparison with JAK 2V617F-mutated and CALR- mutated genotypes

88. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

89. SUSPENSION OF TREATMENT WITH BCR-ABL INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE WITHIN OF THE CLINICAL ASSISTANCE PRACTICE: SPANISH EXPERIENCE IN A TOTAL OF 236 CASES

90. Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes

91. PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

92. PS1465 SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL

93. PF415 EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIAL

96. Sequencing the genomes of an entire mammalian order: an international collaborative effort by Lagomorph Genomics Consortium (LaGomiCs)

97. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

98. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project

99. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia

Catalog

Books, media, physical & digital resources